Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (8716)	3/10/1999 2:56:00 AM
From: MoneyMade	Read Replies (3) \| Respond to of 15987

Final trial eh....looks good! "ImClone starts final trial of cancer drug" By Maggie Fox, Health and Science Correspondent WASHINGTON, March 9 (Reuters) - A small biotechnology company said on Tuesday it had started final trials of a new cancer drug that has so far shown good results in patients. New York based ImClone (Nasdaq:IMCL - news) said it had received the go-ahead from the U.S. Food and Drug Administration (FDA) to start Phase III trials of the drug, which is the final stage before seeking approval. As a result of the green light from the FDA, Germany's Merck KgaA, which signed an agreement with ImClone in December to distribute the drug in Europe, gave ImClone a $5 million ''milestone'' payment.